Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02639728 · ClinicalTrials.gov registry record · NA
The Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery.
A NA study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT02639728: Completed NA study, sponsored by Cedars-Sinai Medical Center.
NCT02639728 is a NA study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02639728, a NA study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The effects of coffee have been shown to act as a colonic stimulant. Caffeinated coffee stimulates colonic activity, most notably in the transverse/descending colon, in magnitude similar to a meal, 60% stronger than water, and 23% stronger than decaffeinated coffee. \[1\] Moreover, the consumption of both water and caffeine causes a decrease in the rectal sensory threshold for the desire to defecate, while anal sphincter pressure after caffeine intake is significantly higher than after water intake. This may result in an earlier desire to defecate. \[2\] Coffee has also been shown to have an effect on defecation by increasing rectal tone by 45% (measured with a barostat) thirty minutes after consumption. \[3\]
Primary Outcome
Time to first flatus and/or bowel movement as assessed twice per day by inquiry from the primary team and study investigators.
Interventions
- OTHER Regular Coffee
- OTHER Decaffeinated coffee
- OTHER Warm water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-11 |
| Est. Completion | 2022-03-23 |
| Phase | NA |
What the finished NCT02639728 record still lists
NCT02639728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Regular Coffee is the first listed.
NCT02639728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02639728 about?
NCT02639728 is a clinical study titled "The Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery.". The effects of coffee have been shown to act as a colonic stimulant. Caffeinated coffee stimulates colonic activity, most notably in the transverse/descending colon, in magnitude similar to a meal, 60% stronger than water, and 23% stronger than decaffeinated coffee. \[1\] Moreover, the consumption o...
What is the current status of trial NCT02639728?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2013-11. Estimated completion is 2022-03-23.
What interventions are being tested in trial NCT02639728?
The interventions under investigation include: Regular Coffee (OTHER), Decaffeinated coffee (OTHER), Warm water (OTHER).
Who is sponsoring clinical trial NCT02639728?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02639728's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia